Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) had its price target dropped by investment analysts at Barclays from $48.00 to $41.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the specialty pharmaceutical company’s stock. Barclays‘s price objective points to a potential upside of 62.50% from the company’s previous close.
A number of other research analysts have also recently issued reports on COLL. Truist Financial started coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 9th. They issued a “buy” rating and a $49.00 price target for the company. Piper Sandler dropped their price objective on shares of Collegium Pharmaceutical from $43.00 to $28.00 and set a “neutral” rating on the stock in a report on Friday, November 6th. Weiss Ratings raised Collegium Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, November 9th. Needham & Company LLC reduced their target price on Collegium Pharmaceutical from $46.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, November 5th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $35.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $44.00.
View Our Latest Report on COLL
Collegium Pharmaceutical Stock Performance
Shares of Collegium Pharmaceutical stock traded down $0.09 during midday trading on Monday, hitting $25.23. The company had a trading volume of 39,323 shares, compared to its average volume of 581,390. The stock has a market cap of $784.15 million, a price-to-earnings ratio of 25.18, a PEG ratio of 0.79 and a beta of 0.74. The company has a quick ratio of 0.87, a current ratio of 1.01 and a debt-to-equity ratio of 3.44. The company has a fifty day simple moving average of $23.04 and a 200 day simple moving average of $32.26. Collegium Pharmaceutical has a 12-month low of $21.43 and a 12-month high of $50.79.
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last released its earnings results on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.10. The company had revenue of $216.34 million for the quarter, compared to the consensus estimate of $216.03 million. Collegium Pharmaceutical had a net margin of 4.68% and a return on equity of 85.14%. Collegium Pharmaceutical’s revenue was up 67.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.25 EPS. As a group, analysts predict that Collegium Pharmaceutical will post 6.42 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Collegium Pharmaceutical
Large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in Collegium Pharmaceutical during the 3rd quarter worth approximately $36,000. Global Retirement Partners LLC lifted its stake in Collegium Pharmaceutical by 530.3% during the 3rd quarter. Global Retirement Partners LLC now owns 2,017 shares of the specialty pharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,697 shares during the period. PNC Financial Services Group Inc. boosted its holdings in shares of Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 418 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of Collegium Pharmaceutical by 9.3% in the 1st quarter. Assetmark Inc. now owns 3,923 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 335 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Collegium Pharmaceutical by 15.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,940 shares of the specialty pharmaceutical company’s stock valued at $132,000 after acquiring an additional 778 shares during the last quarter.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium’s products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.
See Also
- Five stocks we like better than Collegium Pharmaceutical
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
